682 results on '"DiBonaventura, Marco"'
Search Results
2. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial
3. Comparing g-computation, propensity score-based weighting, and targeted maximum likelihood estimation for analyzing externally controlled trials with both measured and unmeasured confounders: a simulation study
4. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial
5. Costs and Treatment Patterns Among Patients with Atopic Dermatitis Using Advanced Therapies in the United States: Analysis of a Retrospective Claims Database
6. Real-World Effectiveness of Newly Initiated Systemic Therapy for Atopic Dermatitis in the United States: A Claims Database Analysis
7. Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis
8. Predictors of nonresponse to dupilumab in patients with atopic dermatitis: A machine learning analysis
9. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial
10. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial
11. Symptom burden of patients with moderate-to-severe atopic dermatitis
12. Impact of elranatamab on quality of life: Patient‐reported outcomes from MagnetisMM‐3
13. Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma
14. Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes
15. Psychosocial Comorbidities and Health Status Among Adults with Moderate-to-Severe Atopic Dermatitis: A 2017 US National Health and Wellness Survey Analysis
16. The Economic and Psychosocial Comorbidity Burden Among Adults with Moderate-to-Severe Atopic Dermatitis in Europe: Analysis of a Cross-Sectional Survey
17. Assessment of algorithms for identifying patients with triple-class refractory multiple myeloma using real-world data.
18. The Epidemiology of Herpes Zoster and Postherpetic Neuralgia in China: Results from a Cross-Sectional Study
19. Rapid Improvement of Itch Associated With Atopic Dermatitis With Abrocitinib Is Partially Independent of Overall Disease Improvement: Results From Pooled Phase 2b and 3 Monotherapy Studies
20. P-249 The association between age, performance status, frailty and outcomes in real-world clinical practice among patients with triple-class exposed multiple myeloma
21. Comparing how well abrocitinib and dupilumab treat atopic dermatitis signs and symptoms: a plain language summary
22. P-248 Real-world outcomes of triple-class exposed multiple myeloma patients by treatment experience: the assocaition of prior lines and penta-refractoriness with progression-free and overall survival
23. P-474 The effect of elranatamab on patient-reported outcomes in patients with relapsed/refractory multiple myeloma naïve and exposed to BCMA-directed therapies: results from the MagnetisMM-3 study
24. P-250 The relationship of extramedullary disease and high-risk cytogenetics on real-world outcomes among patients with triple-class exposed multiple myeloma
25. P-298 Retrospective study of treatment patterns and clinical outcomes by race in patients with triple-class-exposed multiple myeloma treated in a real-world setting
26. Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2
27. P924: TREATMENT PATTERNS OF TRIPLE-CLASS REFRACTORY (TCR) MULTIPLE MYELOMA (MM) ACROSS THE UNITED STATES (US), CANADA, AND WESTERN EUROPE: A REAL-WORLD OBSERVATIONAL CHART REVIEW STUDY
28. P957: AN INDIRECT COMPARISON OF ELRANATAMAB’S (ELRA) OBJECTIVE RESPONSE RATE (ORR) FROM MAGNETISMM-3 (MM-3) VERSUS REAL-WORLD EXTERNAL CONTROL ARMS IN TRIPLE-CLASS REFRACTORY (TCR) MULTIPLE MYELOMA (MM)
29. PB2100: REAL-WORLD TREATMENT PATTERNS OF TRIPLE-CLASS REFRACTORY (TCR) MULTIPLE MYELOMA (MM) ACROSS THE UNITED STATES (US), CANADA, AND WESTERN EUROPE: A RETROSPECTIVE CHART STUDY
30. Abrocitinib efficacy and safety in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND study
31. Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data
32. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial
33. Use of the SF-36v2 Health Survey as a Screen for Risk of Major Depressive Disorder in a US Population-based Sample and Subgroup With Chronic Pain
34. The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe
35. Correction to: Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes
36. Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States
37. Improvements in Disease Activity Partially Mediate the Effect of Tofacitinib Treatment on Generic and Disease-Specific Health-Related Quality of Life in Patients with Ulcerative Colitis: Data from the OCTAVE Program
38. The Association Between Body Mass Index and Health and Economic Outcomes in the United States
39. Psychometric validation of the work productivity and activity impairment questionnaire in ulcerative colitis: results from a systematic literature review
40. Gastroenterologists’ Perceptions Regarding Ulcerative Colitis and Its Management: Results from a Large-Scale Survey
41. Health Status, Work Productivity, and Costs Associated with Diabetic Peripheral Neuropathy
42. Abrocitinib monotherapy in Investigator’s Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life
43. The Patient-Related Burden of Pegylated-Interferon-α Therapy and Adverse Events among Patients with Viral Hepatitis C in Japan
44. Anxiety and Depression Associated With Caregiver Burden in Caregivers of Stroke Survivors With Spasticity
45. Health-related Quality of Life Improvements with Abrocitinib By Clinical Response Status in Patients with Moderate-to-severe Atopic Dermatitis
46. Burden of Gastrointestinal Disease in the United States: 2012 Update
47. The societal burden of chronic pain in Japan: an internet survey
48. Predictors of self-reported benign prostatic hyperplasia in European men: analysis of the European National Health and Wellness Survey
49. Incorporating Indirect Costs into a Cost-Benefit Analysis of Laparoscopic Adjustable Gastric Banding
50. The Burden of Illness for Patients with Viral Hepatitis C: Evidence from a National Survey in Japan
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.